Related Experiment Video
Updated: Jun 18, 2025

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
Published on: March 16, 2018
A peripherally acting μ-opioid receptor antagonist for treating opioid-associated tinnitus: A case report
Satoru Ogawa1, Fumimasa Amaya1
1Department of Pain Management and Palliative Care Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Background:
The use of opioids occasionally causes tinnitus. However, there is a paucity of data regarding the use of peripherally acting μ-opioid receptor antagonists for opioid-associated tinnitus in patients with cancer.
Actual Case:
A 74-year-old male with pancreatic cancer complained of abdominal pain. Two days after initiating oxycodone therapy, the patient experienced tinnitus during body movements. Although peripheral tinnitus disappeared after discontinuing oxycodone, it reappeared with hydromorphone or tapentadol administration.
Possible Courses Of Action:
Drug cessation is a preferred intervention for drug-induced tinnitus; however, the cessation of opioids may not be feasible in patients with cancer who are already taking opioids.
Formulation Of A Plan:
Based on the presumed mechanism of peripheral tinnitus, the use of peripherally acting μ-opioid receptor antagonists was planned, and 200 μg/day of naldemedine was prescribed for tinnitus relief.
Outcome:
Tinnitus disappeared immediately after initiating naldemedine, and the pain was well-controlled. The effect was preserved after increasing or switching opioids.
Lessons:
The use of peripherally acting μ-opioid receptor antagonists may be an option to treat opioid-associated tinnitus without compromising the analgesic effects.
View:
Further clinical data regarding the secondary effect of peripherally acting μ-opioid receptor antagonists on opioid-associated complications other than constipation are required.
Insights
Peripherally acting μ-opioid receptor antagonists effectively treated opioid-associated tinnitus in a cancer patient. This approach managed tinnitus without impacting pain control, offering a new therapeutic option.
Area of Science:
- Oncology
- Pharmacology
- Pain Management
Background:
- Opioid use can cause tinnitus, a condition with limited research regarding management in cancer patients.
- Opioid-induced tinnitus poses a challenge, as discontinuing opioids may compromise pain management in cancer care.
Observation:
- A pancreatic cancer patient developed tinnitus during opioid therapy (oxycodone, hydromorphone, tapentadol).
- Tinnitus resolved upon opioid cessation but recurred with re-administration, indicating a direct drug effect.
Findings:
- Naldemedine, a peripherally acting μ-opioid receptor antagonist, was administered at 200 μg/day for tinnitus relief.
- Tinnitus resolved immediately upon naldemedine initiation, and pain control was maintained.
Implications:
- Peripherally acting μ-opioid receptor antagonists may offer a viable strategy for managing opioid-associated tinnitus in cancer patients.
- This treatment allows for continued opioid analgesia while addressing tinnitus, improving patient quality of life.
- Further research is needed to explore the broader effects of these antagonists on opioid-related complications beyond constipation.
More Related Videos
07:23Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
Published on: July 29, 2014
12:21The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration
Published on: November 26, 2015
Related Concept Videos
Analgesia and Pain Management
Opioid Receptors: Overview
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Opioid Analgesics: Morphine and Other Natural Cogeners